These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 23478586)

  • 41. FDG PET/CT as a prognostic test after 90Y radioembolization in patients with metastatic hepatic disease.
    Zalom M; Yu R; Friedman M; Bresee C; Waxman A
    Clin Nucl Med; 2012 Sep; 37(9):862-5. PubMed ID: 22889775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
    Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment response in liver metastases following 90Y SIR-spheres: an evaluation with PET.
    Lin M; Shon IH; Wilson R; D'Amours SK; Schlaphoff G; Lin P
    Hepatogastroenterology; 2007; 54(75):910-2. PubMed ID: 17591090
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy.
    Gulec SA; Suthar RR; Barot TC; Pennington K
    Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1289-95. PubMed ID: 21461737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance.
    Vouche M; Salem R; Miller FH; Lemort M; Vanderlinden B; De Becker D; Hendlisz A; Flamen P
    Clin Imaging; 2015; 39(3):454-62. PubMed ID: 25724225
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment.
    Niekel MC; Bipat S; Stoker J
    Radiology; 2010 Dec; 257(3):674-84. PubMed ID: 20829538
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Does a novel penalized likelihood reconstruction of 18F-FDG PET-CT improve signal-to-background in colorectal liver metastases?
    Parvizi N; Franklin JM; McGowan DR; Teoh EJ; Bradley KM; Gleeson FV
    Eur J Radiol; 2015 Oct; 84(10):1873-8. PubMed ID: 26163992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 50. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
    Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
    Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
    Goshen E; Davidson T; Zwas ST; Aderka D
    Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer.
    Heijmen L; ter Voert EE; Oyen WJ; Punt CJ; van Spronsen DJ; Heerschap A; de Geus-Oei LF; van Laarhoven HW
    PLoS One; 2015; 10(4):e0120823. PubMed ID: 25831053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does multidetector CT attenuation change in colon cancer liver metastases treated with 90Y help predict metabolic activity at FDG PET?
    Tochetto SM; Rezai P; Rezvani M; Nikolaidis P; Berggruen S; Atassi B; Salem R; Yaghmai V
    Radiology; 2010 Apr; 255(1):164-72. PubMed ID: 20308454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
    Findlay M; Young H; Cunningham D; Iveson A; Cronin B; Hickish T; Pratt B; Husband J; Flower M; Ott R
    J Clin Oncol; 1996 Mar; 14(3):700-8. PubMed ID: 8622014
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E; Aras G; Kucuk NO
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer.
    Heijmen L; de Geus-Oei LF; de Wilt JH; Visvikis D; Hatt M; Visser EP; Bussink J; Punt CJ; Oyen WJ; van Laarhoven HW
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1858-67. PubMed ID: 22945372
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
    Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
    Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction.
    Sheikhbahaei S; Wray R; Young B; Mena E; Taghipour M; Rahmim A; Subramaniam RM
    Nucl Med Commun; 2016 Mar; 37(3):231-8. PubMed ID: 26575392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anatomic versus Metabolic Tumor Response Assessment after Radioembolization Treatment.
    Jongen JMJ; Rosenbaum CENM; Braat MNGJA; van den Bosch MAAJ; Sze DY; Kranenburg O; Borel Rinkes IHM; Lam MGEH; van den Hoven AF
    J Vasc Interv Radiol; 2018 Feb; 29(2):244-253.e2. PubMed ID: 29249594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.